SOST and osteogenesis imperfecta: It was demonstrated to improve bone formation in hSOSTki mice, OVX, and osteogenesis imperfecta mice without affecting aortic aneurysm and atherosclerotic development and proved nontoxic to healthy rodents even at an ultrahigh dose.143,144 Due to these efficacies, it was granted orphan drug designation for osteogenesis imperfecta by the FDA in 2019 (DRU-2019-6966), which may pioneer a novel target for developing next-generation sclerostin inhibitors.